Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487554 | 0.84 | BRD4 (0.42) | BRD4HTR6PTPN11ALDH1A1CYP1A2 | |
| SCHEMBL8321386 | 0.80 | BRD4 (0.44) | BRD4HTR6PTPN11ALDH1A1CYP1A2 | |
| SCHEMBL8325111 | 0.80 | BRD4 (0.44) | BRD4HTR6PTPN11CYP2C19CA12 | |
| SCHEMBL1044745 | 0.79 | BRD4 (0.55) | BRD4HTR6CYP2C19PTGER4CYP2C9 | |
| SCHEMBL13746023 | 0.79 | BRD4 (0.45) | BRD4HTR6PTPN11CA12CA1 | |
| SCHEMBL1487581 | 0.79 | BRD4 (0.43) | BRD4HTR6PTPN11ALDH1A1CYP1A2 | |
| SCHEMBL1487552 | 0.78 | PTPN11 (0.47) | BRD4HTR6PTPN11CA12CA1 | |
| SCHEMBL2753498 | 0.78 | PDPK1 (0.49) | BRD4HTR6PTPN11CDK8IMPDH2 | |
| SCHEMBL1487551 | 0.77 | BRD4 (0.42) | BRD4HTR6PTPN11CA12CA1 | |
| SCHEMBL14031024 | 0.76 | IMPDH2 (0.47) | ALDH1A1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060270646-A1 | Jnk inhibitors | EISAI CO., LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270646-A1 | Jnk inhibitors | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1384/4885HTR6 2354/4885PTPN11 1642/4885 |
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | BRD4 1339/4885HTR6 2381/4885PTPN11 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.